Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock

At the EuroPCR 2025, Edwards Lifesciences (EW) has announced new economic and clinical evidence on severe aortic stenosis (AS). The results of a new real-world study, comprising more than 24,000 patients, demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outcomes.Presented as a late-breaking clinical trial, the data further contributes to the extensive body of research on this disease. The development i ...